IFN-beta

IFN-beta

IFN-beta Molekülinformation

Molecule Name
Interferon beta
Molekülalias
IFNB1,Interferon beta,IFN-beta,IFB,IFNB
Drug Development Progress
Anzahl der klinischen Arzneimittel6
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
Interferon Beta 1,Interferon, Beta 1, Fibroblast,IFNB,IFB,IFF,Interferon-beta,IFN-beta,Fibroblast interferon,IFNB1,Interferon beta
Molekülhintergrund
Interferon beta(IFN beta) is type I interferon cytokine that plays a key role in the innate immune response to infection, developing tumors and other inflammatory stimuli. Signals via binding to high-affinity (IFNAR2) and low-affinity (IFNAR1) heterodimeric receptor, activating the canonical Jak-STAT signaling pathway resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response, such as antiviral proteins, regulators of cell proliferation and differentiation, and immunoregulatory proteins. IFNB1 is more potent than interferon-alpha (IFN-alpha) in inducing the apoptotic and antiproliferative pathways required for control of tumor cell growth (By similarity)

IFN-beta Produktliste

Species
  • Human(2)
  • Mouse(1)
Tag
  • His Tag & Avi Tag(2)
  • Fc Tag(1)
Host
  • HEK293(3)
Conjugate
  • Biotin-labeled(2)
  • Unconjugated(1)
Grade
  • RUO(3)
Low Endotoxin
  • No(3)
MoleculeCat. No.Product NameArtHostStructurePurityActivitySize&PriceAdd to Cart
IFN-beta
Human IFN-beta Protein, Fc Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$350.00

100ug
IFN-beta
Biotinylated Human IFN-beta Protein, His,Avitag™ (MALS & SPR verified)
Human
HEK293
MALSSDS-PAGE
SPR

$360.00

25ug
IFN-beta
Biotinylated Mouse IFN-beta Protein, His,Avitag™ (MALS & SPR verified)
Mouse
HEK293
MALSSDS-PAGE
SPR

$360.00

25ug
You Have Viewed 1-3 Of 3 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
DazukibartPF-06823859Phase 3 ClinicalPfizer Inc
Dermatomyositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Muscular Diseases; Myositis; Polymyositis
Details
Peginterferon beta-1a (CinnaGen)Phase 3 ClinicalCinnagen
Multiple Sclerosis, Relapsing-Remitting
Details
VSV-IFNbeta-NISPhase 2 ClinicalVyriad
Angioimmunoblastic T-cell Lymphoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Histiocytoma; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Multiple Myeloma; Mycosis Fungoides; Myelodysplastic Syndromes; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
VSV-hIFNbeta-NIS (University of Tennessee)Phase 1 ClinicalThe University Of Tennessee
Endometrial Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Multiple Myeloma
Details
MEM-288MEM-288Phase 1 ClinicalMemgen
Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
SCD-153SCD-153Phase 1 ClinicalInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Johns Hopkins University, Sun Pharma Advanced Research Company Ltd
Alopecia Areata
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
PropagermaniumSK-818; SK-818CApprovedSanwa Kagaku Kenkyusho Co LtdSerocionJapanHepatitis BSanwa Kagaku Kenkyusho Co Ltd1994-01-01
Hepatitis B
Details
Customer Reviews